Change Password!
Reset Password!
48-week supplementation of Raloxifene and Cholecalciferol enhances spine bone density and reduces hip bone loss in postmenopausal women with severe osteopenia (bone loss), possibly lowering fracture risk.
Combination of selective estrogen receptor modulator and Vitamin D boosts prevents bone loss in postmenopausal women, according to a study published in ‘JBMR Plus’.
Sungjae Shin and colleagues initiated a randomized trial that enrolled 112 postmenopausal women with osteopenia. Participants were randomly assigned to receive either Raloxifene 60 mg plus Cholecalciferol 800 IU given daily (RalD group) or just Cholecalciferol 800 IU daily (VitD group) for 48 weeks. Alterations in the bone mineral density (BMD) at the lumbar spine and total hip were deliberate using standard techniques.
After 48 weeks, the RalD group showed a noteworthy increase in lumbar spine BMD (2.6% increase versus -0.6% decrease in the VitD group) and less total hip BMD loss (-0.3% versus -2.9%). The beneficial effect on lumbar spine BMD persisted even after adjusting for age, BMI, baseline BMD T-score, and other factors. Subgroup analysis revealed a stronger effect of RalD in participants with severe osteopenia.
Raloxifene with Cholecalciferol drastically improves bone health compared to Cholecalciferol alone in women after menopause suffering from osteopenia, particularly benefiting those with severe bone density deficits.
JBMR Plus
A randomized controlled trial of the effect of Raloxifene plus Cholecalciferol versus Cholecalciferol alone on bone mineral density in postmenopausal women with osteopenia
Sungjae Shin et al.
Comments (0)